LYRA Lyra Therapeutics
- 0.383
- +0.015+4.19%
- 0.388
- +0.005+1.28%
Lyra Therapeutics News
Jefferies Cuts Lyra to Hold in Wake of Failed Phase 3 Study
Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50
Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)
Sell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding Concerns
BTIG Downgrades Lyra Therapeutics (LYRA) to a Hold
Buy Rating Affirmed for Lyra Therapeutics Amid Strong Phase 3 Prospects for LYR-210
Lyra Therapeutics Analyst Ratings
Buy Rating for Lyra Therapeutics Backed by Upcoming Catalysts and Market Potential
Buy Rating Affirmed for Lyra Therapeutics Amid Favorable LYR-210 Trial Outcomes and Strategic CRS Market Positioning
Lyra Therapeutics Analyst Ratings
Lyra Therapeutics Analyst Ratings
Lyra Therapeutics Analyst Ratings
Optimistic Buy Rating for Lyra Therapeutics' LYR-210 Amidst Phase 3 Trial and Market Opportunity
BTIG Keeps Their Buy Rating on Lyra Therapeutics (LYRA)
Lyra Therapeutics' Nasal Implants Show Promising Results: A Buy Rating Supported by Phase 2 BEACON Trial and Upcoming Phase 3 ENLIGHTEN Trial
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (VCEL), Sana Biotechnology (SANA) and Lyra Therapeutics (LYRA)
Analysts Conflicted on These Healthcare Names: BioAtla (BCAB), Lyra Therapeutics (LYRA) and Apollo Medical Holdings (AMEH)
BTIG Assumes Lyra Therapeutics at Buy, Announces Price Target of $15
Lyra Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target
Analysis
Price Target
No Data
